Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07645833
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/SNot Yet RecruitingPhase 3
NCT07645833Not Yet Recruiting
Phase 3
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/S
NCT07645053
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal SurgeryHospital Edmundo VasconcelosCompletedPhase 1
NCT07645053Completed
Phase 1
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal...Hospital Edmundo Vasconce...
NCT07644026
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting
NCT07644026Not Yet Recruiting
—
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology &...
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07646561
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El ManarCompleted
NCT07646561Completed
—
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El Manar
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07644936
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisNot Yet Recruiting
NCT07644936Not Yet Recruiting
—
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Speci...
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07644169
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG) in Healthy Adults Following PG ExposureAmerican Beverage AssociationNot Yet RecruitingNot Applicable
NCT07644169Not Yet Recruiting
Not Applicable
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG)...American Beverage Associa...
NCT07645300
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD TrialMichael E. DeBakey VA Medical CenterNot Yet RecruitingPhase 2
NCT07645300Not Yet Recruiting
Phase 2
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD TrialMichael E. DeBakey VA Med...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07645378
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaCentre for the AIDS Programme of Research in South AfricaNot Yet RecruitingNot Applicable
NCT07645378Not Yet Recruiting
Not Applicable
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervica...Centre for the AIDS Progr...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646431
Comparative Effects Of Clamshell And Short Arc Quadriceps Exercises In Patellofemoral PainGreen International UniversityCompletedNot Applicable
NCT07646431Completed
Not Applicable
Comparative Effects Of Clamshell And Short Arc Quadriceps Exercises In Patellofe...Green International Unive...
NCT07643935
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of ResponseCentral Hospital, Nancy, FranceNot Yet Recruiting
NCT07643935Not Yet Recruiting
—
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timin...Central Hospital, Nancy,...
NCT07646093
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in ChildrenHospital Universitario de CaracasCompletedNot Applicable
NCT07646093Completed
Not Applicable
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillect...Hospital Universitario de...
Result Breakdown
Not yet recruiting14 (70%)
Completed4 (20%)
Recruiting2 (10%)
not_applicable6 (30%)
Not Specified6 (30%)
Phase 14 (20%)
Phase 32 (10%)
Phase 22 (10%)